In addition, it is noteworthy that the combination of anlotinib with PD-1 checkpoint inhibitors counteracted the immune suppression induced by PD-L1 upregulation after monotherapy, ultimately inducing the regression of neuroblastoma [29]. This evidence concerns the gene CD274 and neuroblastoma.